Quantum Biopharma (QNTM) Total Non-Current Liabilities (2020 - 2026)
Quantum Biopharma (QNTM) posted Total Non-Current Liabilities of $9.8 million for Q1 2026, up 61.43% sequentially from $6.1 million in Q4 2025.
Quantum Biopharma (QNTM) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Quantum Biopharma has reported Total Non-Current Liabilities for 6 years, with the latest figure at $9.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (changed N/A YoY) and the FY2025 annual result came in at $6.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities climbed to $9.8 million in Q1 2026 per QNTM's latest filing, from $6.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $9.8 million in Q1 2026 and troughed at -$522884.0 in Q1 2022.
- A 4-year average of $1.5 million and a median of -$130383.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 75.1% in 2022, down 99.53% in 2022.
- Over 4 years, Total Non-Current Liabilities stood at $38004.0 in 2022, then tumbled by 443.08% to -$130383.0 in 2023, then jumped by 4746.54% to $6.1 million in 2025, then surged by 61.43% to $9.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.8 million, $6.1 million, and -$130383.0 for Q1 2026, Q4 2025, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.78 Mn |
| Dec 31, 2025 | 6.06 Mn |
| Sep 30, 2023 | -130,383.00 |
| Jun 30, 2023 | -122,351.00 |
| Mar 31, 2023 | -450,544.00 |
| Dec 31, 2022 | 38,004.00 |
| Sep 30, 2022 | -388,481.00 |
| Jun 30, 2022 | -425,620.00 |
| Mar 31, 2022 | -522,884.00 |
| Dec 31, 2021 | 8.07 Mn |
| Sep 30, 2021 | -1.43 Mn |
| Jun 30, 2021 | -1.71 Mn |
| Mar 31, 2021 | -2.00 Mn |
| Dec 31, 2020 | 4.21 Mn |
| Sep 30, 2020 | -2.61 Mn |